To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Zymeworks confirms $773m buyout offer from All Blue Capital
Zymeworks, a Vancouver-based provider of multifunctional biotherapeutics, has confirmed its receipt of an unsolicited, non-binding acquisition proposal from an affiliate of All Blue Capital.
